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BreastAbstract Objective: To evaluate the role of conventional and functional MRI in diagnosis of
breast masses.
Patients and methods: This study included 34 female patients who presented clinically by breast
mass and/or had abnormal sonomammographic ﬁndings and referred from General surgery
Department for MRI assessment. The MRI results were correlated with pathological results for
all cases.
Results: Those 34 patients were classiﬁed pathologically into 21 patients with benign breast lesion
(21/34) (61.8%), 10 patients with malignant lesion (29.4%) and 3 patients with high risk lesion
(8.8%). The type III intensity curve was the most depicted type in the malignant breast lesion
(60%), while type Ia curve was the most depicted type in the benign lesions (61.8%). Out of 25
patients without restricted diffusion; 19 patients showed benign lesions (76%) and out of 9 patients
with restricted diffusion; 6 patients showed malignant lesion (66.7%). Out of 17 patients with
choline trace; 9 patients were malignant, 5 were benign and 3 were with high risk lesion.
Conclusion: DCE-MRI of the breast had a higher sensitivity for breast cancer detection and more
accurate in delineation of the disease extension. The breast MRI with three parameters (DCE-MRI,
DWI, and MRS) increased the diagnostic accuracy of the breast cancer.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is a major health problem. Unlike many other
forms of cancers, awareness among women of the risks associ-
ated with the breast cancer is high and derives from many
sources including health education programs, extensive media
coverage and ﬁrsthand knowledge from friends and relatives.
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mography, which has a false negative rate of 10–25%.
Furthermore, mammography has limitations in its ability to
accurately establish the extent of the disease in the breast can-
cer for some subsets of women undergoing treatment. It may
underestimate the extent of lobular carcinoma up to 25% of
cases. That’s why interest has focused on MRI as an adjunct
to mammography (1).
Dynamic contrast enhancement MRI (DCE-MRI) of the
breast has a high sensitivity for breast cancer detection and
has recently been shown to be the most sensitive breast screen-
ing technique for women at high risk. DCE-MRI is also more
accurate than mammography or U/S. for delineation of the
extent of the disease in patient with recent diagnosis of cancer.
The high sensitivity of clinical breast DCE-MRI is due to its
differential enhancement between normal and malignant tissue
on TIWI (2).
Researches on new MRI technique are being conducted to
further increase the speciﬁcity of breast MRI. Diffusion
weighted imaging (DWI) was recently integrated into the stan-
dard breast MRI examination for this purpose. It is a non-
invasive technique that measures the random motion of free
water protons (Brownian motion) and characterizes the tissue
with a mechanism that is different from T1 and T2 relaxation.
The motion of water protons in the tissue is affected by ﬂuid
viscosity, membrane permeability, blood ﬂow and cellularity
of the tissue, for quantiﬁcation of this motion, Apparent
Diffusion Coefﬁcient (ADC) values are used (3).
Diffusion weighted MR imaging detects early changes in
the morphology and physiology of tissues, such as changes
in the permeability of membrane, cell swelling and/or cell lysis
(4,5). Since 2002 many studies revealed the usefulness of DWI
in differentiation of malignant from benign tumor of the
breast. In these studies, sensitivity in the range of 80–96%
and speciﬁcity in the range of 46–91% were reported (6,7).
Moreover, DWI has a potential role for characterization of
breast masses and treatment monitoring after chemotherapy
(8,9).
Promising ﬁndings from the preliminary DWI studies of the
breast have shown signiﬁcantly lower ADC measures for
breast carcinoma than for benign breast lesion or normal tis-
sue. The lower ADC in malignancy is primarily attributed to
higher cell density causing increased restriction of extracellular
matrix and increased fraction of signal coming from intracellu-
lar water. A recent study reported high accuracy for character-
izing enhancing breast masses through multivariate
combination of DWI and DCE-MRI (10).
In addition to morphologic and kinetic analyses, molecular
information has been expected to be useful for diagnosis of the
breast disease. In vivo proton (H) Magnetic Resonance
Spectroscopy (MRS) of the breast which provides molecular
information obtained in non-invasive manner, has shown that
the choline is generally not detectable in normal breast tissue.
In several studies performed on 1.5 T MR imagers, investiga-
tors have reported sensitivities of 70–100% and of 67–100%
speciﬁcities for breast MRS (11).
2. Patients and methods
This study was carried out on 34 female patients who pre-
sented clinically by breast mass and/or abnormal sono-
mammographic ﬁndings. Those patients were referred toRadio-diagnosis and Medical Imaging Department from
wards and clinics of the surgery department for MRI evalua-
tion and assessment.
This study was performed at the period from November
2012 to November 2013. Approval of Research Ethics
Committee (REC) of Tanta University and informed written
consent were obtained from all participants in the study after
full explanation of the beneﬁts and risks of the procedure.
Privacy and conﬁdentiality of all patient data were guaranteed.
All data provision were monitored and used for scientiﬁc
purpose only.
All patients of our study were subjected to the followings:
I-Full history taking.
II-Clinical examination: General examination and local
breast examination and examination of the ipsilateral and con-
tralateral axillary, cervical and supraclavicular lymph nodes.
III-MRI Examination:
*Studies were obtained using a closed MRI machine – 1.5-T
MRI system (Signa; GE Medical Systems, Milwaukee, USA)
equipped with bilateral dedicated breast coils.
*Patients were placed on top of specialized phased array
breast coil in the prone position to allow both breasts to nat-
urally hang inside the loop of coil. We ensured that both
breasts ﬁtted entirely within the coil, positioning pads and
cushions were used to eliminate skin folds within the coil near
axilla and under the breast.
*Premenopausal women underwent the examination ideally
on day 6–13 of the menstrual cycle in order to reduce the risk
of false positives except for some urgent cases.
*Transverse, sagittal and coronal plane localization scans
were done and the following sequences were taken.
i-Fast spin echo (FSE)T1WI (TR; 500 ms, TE; 15 ms).
ii-T2WI with fat suppression (TR; 5600 ms, TE; 59 ms) in
the transverse plane; slice thickness; 4 mm, spacing; 1 mm,
image matrix; 320 · 314; 4 NEX.
*After conﬁrmation of the lesion location in T2WI, DWI of
the entire breast was performed in the transverse plane with a
single excitation echo planner imaging (SE-EPI) sequence. A
diffusion sensitive gradient was applied along the X-, Y- and
Z-axes. The main parameters of DWI were; TR; 8400 ms
TE; 98 ms, Slice thickness; 4 mm, spacing; 1 mm, image
matrix; 174 · 349, 2 NEX; ﬁeld of vision (FOV); 33 · 30 cm;
b values were 50, 400, and 800 s/mm2. DWI was always per-
formed prior to contrast enhancement to avoid the effect of
contrast material.
*Dynamic contrast MRI was performed by two dimen-
sional fast spoiled gradient recalled echo with fat suppression
in T1WI (TR; 4.3 ms TE; 1.3 ms, ﬂip angle; 80 axial scan,
FOV 34 · 34 cm, image matrix 448 · 322, 1 NEX, slice thick-
ness; 1 mm, spacing; 1 mm). T1WI were obtained in the trans-
verse plane before, and immediately after bolus injection of
0.2 mmol Gadopentate dimeglumine/kg of body weight at a
rate of 4 ml/s, followed by 20 ml saline ﬂush using an auto-
matic injector. Five phase dynamic images were obtained 1,
2, 3, 4, 5 min. respectively. Dynamic analysis was performed
through generation of percent enhancement versus time curves
performed through positioning of ROI at least for all identiﬁed
enhancing lesion with a diameter >5 mm and mass-like mor-
phology according to MR Breast Imaging Reporting And
Data System(BI-RADS) classiﬁcation.
Table 1 Histopathological classiﬁcation of 34 female patients
of our study.
Pathological results No. %
(i) Malignant lesions 10 29.4
Ductal carcinoma in situ (DCIS) 1
Inﬁltrating ductal carcinoma (IDC) 3
Invasive lobular carcinoma (ILC) 1
Recurrent/residual mammary duct carcinoma 5
(ii) High risk lesions 3 8.8
Mammary duct dysplasia 1
Fibroadenomatoid atypical hyperplasia 2
(iii) Benign lesions 21 61.8
Neoplastic
Fibroadenoma 6
Lipoma 1
Fibroadenolipoma (hamartoma) 1
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with a single voxel technique with ﬁeld strength of 1.5 T.
Typical acquisition parameter includes an TE of 135 ms or
longer to reduce lipid signal and TR of 1.5–3 s. The median
diameter of the lesion was 20 mm and median volume of 2.2
ML.
*Other features of MR imaging include automated func-
tions like computer aided detection, image registration, multi-
planar reformatting, subtraction, angiogenesis maps, curves,
maximum intensity projection (MIP), and volume summaries.
*Conventional MRI (T1WI and T2WI), DWI (ADC val-
ues), DCE-MRI (TIC type) and MRS ﬁndings of breast
masses for each patient of our study were correlated and com-
pared with surgical and pathological ﬁndings.
*Staging MR imaging is routinely performed on patients
with known breast cancer to determine the extent of the
disease.
Inﬂammatory
Abscess 1
Postoperative
Postoperative scar 3
Seroma 3
Fat necrosis 2
Miscellaneous
Fibroadenosis 2
Fibrocystic changes 2
Total no. 34 100
Table 2 MRI ﬁndings of the breast masses in the 34 studied
female patients.
MR ﬁndings No. %
Enhancing mass 18 52.9
Enhancing foci 7 20.5
Non-enhancing mass 5 14.7
Non-mass enhancement 7 20.5
Cystic lesion 3 8.8
Fibrocystic disease 4 11.8
Suspicious lymphadenopathy 7 20.5
Table 3 MRM classiﬁcation of the 34 cases of our study
according to BI-RADS Lexicon.
Group MRM-BI-RADS
No. %
GI. 18 52.9
BI-RADS 1 0 0
BI-RADS 2 10 29.4
BI-RADS 3 8 23.5
GII. 16 47.1
BI-RADS 4 9 26.5
BI-RADS 5 7 20.6
BI-RADS 6 0 0
Total no 34 1003. Results
This study was carried out on 34 females who presented clini-
cally by breast mass and/or mammo-sonographic abnormali-
ties. All 34 female patients of our study underwent breast
MR examination (conventional and functional) and compared
with pathological ﬁndings of each one.
Out of 34 patients included in this study 21 ones were hav-
ing benign breast lesion (21/34) (61.8%), 10 patients were hav-
ing malignant lesion (10/34) (29.4%) and the remained 3 ones
were having high risk lesion (3/34) (8.8%). Fibroadenoma was
the most common benign breast lesion (6/21) (28.6%), while
the recurrent/residual mammary duct carcinoma was the most
malignant breast lesion (5/10) (50%), followed by inﬁltrating
ductal carcinoma (3/10) (30%) as shown in Table 1.
Out of 34 patients of our study; 18 showed enhancing
breast mass, 7 cases showed enhancing foci and 5 cases showed
non-enhancing mass. The enhancing breast mass was the most
common MR ﬁndings (18/34) (52.9%) as shown in Table 2.
N.B. More than one MR. ﬁndings were detected in the
same patient.
According to BI-RADS lexicon of the MRM (MR mam-
mography) study, those 34 cases were divided into two groups;
G.I; included BI-RADS 1, 2, 3 (i.e. MRM non-suspicious
lesions) and G.II; Included BI-RADS 4, 5, 6 (i.e. MRM suspi-
cious breast lesion). We found that MRM-BIRADS 2 was the
most common MR. pattern (10/34) (29.4%), followed by
MRM BIRADS 4 (9/34) (26.5%) and BI-RADS 3 (8/34)
(23.5%) as shown in Table 3.
The MRM-BI-RADS ﬁndings of the 34 patients of our
study were correlated with Pathological results. Out of GI.
18 patients (with MRM BI-RADS 1, 2, 3), 17 were proved
pathologically to be benign (17/18) (94.4%), while out of
GII. 16 patients (with MRM BI-RADS 4, 5, 6), 10 were
proved to be malignant 10/16 (62.5%), 4 were benign
(4/16) (25%) and 2 were with high risk lesion (2/16)
(12.5%) as shown in Table 4.
All 34 patients underwent DCE-MR for the breast lesion
and classiﬁed according to kinetic intensity curve type. Type
Ia intensity curve was the most common type (21/34)
(61.8%), followed by type III curve (14/34) (41.2%) as shown
in Table 5.NB: The same patient showed more than one type of kinetic
intensity curve especially for those with multiple enhancing
foci.
Table 4 Correlation between MRM ﬁndings and pathological
results (No. = 34).
MRM-BI-RADS Pathological ﬁndings T.
No.
Benign High risk Malignant
No. % No. % No. %
GI. (n= 18)
BI-RADS 1, 2, 3
Non-suspicious
17 94.4 1 5.6 0 0 18
GII. (n= 16)
BI-RADS 4, 5, 6
suspicious
4 25 2 12.5 10 62.5 16
Total no 21 3 10 34
Table 5 Classiﬁcation of 34 patients of our study according to
DCE-MR.
Kinetic intensity curve type No. %
Type I 23
Type Ia (persistent enhancement) 21 61.8
Type Ib (persistent with bowing) 2 5.9
Type II (Plateau curve) 4 11.8
Type III (washout curve) 14 41.2
Total no. 41
Table 6 Correlation between kinetic intensity curve and
pathological ﬁndings.
DCE-MR
kinetic
intensity
curve
Histo-pathological results Total no.
of patients
n= 34
Benign
(n= 21)
High risk
(n= 3)
Malignant
(n= 10)
No. % No. % No. %
Type Ia 13 61.8 3 100 5 50 21
Type Ib 2 100 0 0 0 2
Type II 0 0 0 0 4 40 4
Type III 6 28.6 2 66.7 6 60 14
Total no. of
curve
21 5 15 41
Table 8 Correlation between MRS ﬁndings and pathological
results of the 34 patients of our study.
MRS. ﬁndings Histopathological results Total
no.
Benign High risk Malignant
No. % No. % No. % %
GI. No choline
traces
16 94.1 0 0 1 5.9 17 50
GII. Choline
traces
5 29.4 3 17.6 9 52.9 17 50
Total no. 21 3 10 34 100
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with pathological results of each patient. Type III curve was
the most common type in the pathologically proven malignant
lesion (6/10) (60%), followed by type Ia (5/10) (50%) and type
II (4/10) (40%), while in pathologically proven benign lesionTable 7 Correlation between MR diffusion and ADC value with p
Diﬀusion MR Histo-patho
ADC values Benign
No. %
(A) Non-restricted diﬀusion ADC= 1.7–
2.7 · 103 mm2/S
19 7
(B) Restricted diﬀusion ADC= 0.5–0.9 · 103 mm2/S 2 2the type Ia curve was the most common type (13/21)
(61.8%), followed by type III (6/21) (28.6%) as shown in
Table 6.
All 34 patients of our study underwent DWI and ADC
value measurement for breast masses and classiﬁed into two
groups according to presence or absence of diffusion restric-
tion, GI. included 25 patients without diffusion restriction
and ADC value ranged from 1.7 to 2.7 · 10–3 mm/S. and
GII. Included 9 patients with diffusion restriction and ADC
value was ranged from 0.5 to 0.9 · 10–3/S. These ﬁndings were
correlated and compared with pathological results. Out of 25
patients without restricted diffusion; 19 patients were proven
to be benign lesion (19/25) (76%), 4 patients were proven to
be malignant (4/25) (16%) and only 2 patients were high risk
lesions (2/25) (8%),while out of 9 patients with restricted diffu-
sion; 6 patients were proven to be malignant (6/9) (66.7%), 2
patients with benign lesion (2/9) (22.2%) and only one patient
with high risk lesion (1/9) (11.1%) as shown in Table 7.
Our studied 34 cases were classiﬁed into two groups accord-
ing to their MRS. analysis; GI. Included 17 cases without cho-
line trace and GII. Included 17 cases with choline traces and
these MRS ﬁndings were correlated and compared with patho-
logical results. Out of GI 17 patients without choline traces, 16
were proven to be benign (16/17) (94.1%) and only one patient
was malignant (1/17) (5.9%), while out of GII 17 patients with
choline traces, 9 patients were proven to be malignant (9/17)
(52.9%), 5 patients were benign (5/17) (29.4%) and 3 patients
were high risk lesions (3/17) (17.6%) as shown in Table 8.
Where the condition of positivity shown by various MR
modalities signiﬁes the malignancy proven biopsy and the his-
tologically classiﬁed high risk lesions, the ﬁnal results of DCE-
MRI, DWI and MRS of 34 patients of our study were corre-
lated and compared with pathological results. We found that
DCE-MRI and MRS had the same higher sensitivityathological results.
logical results T. no. %
High risk Malignant
No. % No. %
6 2 8 4 16 25 74
2.2 1 11.1 6 66.7 9 26
Table 9 Final results of DCE-MRI, DWI and MRS in the
studied 34 cases.
Results No. of detectable cases by
DCE-MRI DWI MRS
True +ve 12 7 12
True ve 17 19 16
False +ve 4 2 5
False ve 1 6 1
Sensitivity 92.3% 53.8% 92.3%
Speciﬁcity 81% 90.5% 76.2%
+ve predictive value 75% 77.8% 70.6%
ve predictive value 94.4% 76% 94.1%
Accuracy 85.3% 76.5% 82.4%
MRI in diagnosis of breast masses 1219(92.3%), while DWI had the least sensitivity (53.8%). The
DWI had higher speciﬁcity (90.5%) in comparison with the
DCE-MRI (81%) and MRS (76.2%). DCE-MRI had rela-
tively higher accuracy (85.3%) in comparison with the MRS
(82.4%) and DWI (76.5%) as shown in Table 9.
Fig. 1 (A–M) A young girl aged 11 ys. presented clinically
by palpable Lt. breast lump.
(A) Bilateral medio-lateral oblique views on mammography
showed bilaterally dense breasts (ACR 4) (B) Real-time U/S.
revealed a benign looking macrolobulated hypoechoic left
breast mass, with well-deﬁned border and without detectable
calciﬁcations. (C) Axial T1WI without fat suppression revealed
peripheral and rim hyperintensity, and appeared hypointense
on T2WI with fat suppression. (D) denoting hemorrhagic com-
ponent, while the rest of the lesion exhibiting T2 hyperinten-
sity. (E) T1WI with contrast and delayed post-contrast
T1WI subtracted image (F) show homogenous intense
enhancement of the lesion, without parenchymal distortion.
(G and H) TIC of selected ROI showed Type III (rapid wash
out), inside the lesion, with some areas exhibiting type Ib
curve. (I) MIP of the lesion, sagittal plane, Color code display
images (J) showed no neovascularization of the lesion.
(K) DWI (b800 s/mm2) of the lesion and corresponding
ADC. (L) Revealed areas of high signal intensity on the
DWI and other area of no restricted diffusion showing ADC
value (1.6 · 10–3 mm2/s). (M) Minimal choline trace is
identiﬁed on spectroscopical analysis.
Overall MRI features suggested the equivocal nature of the
lesion, and was ranked BIRADS 4 by MRI (conﬁrmed at
histopathology to be juvenile breast ﬁbroadenoma).
Fig. 2 (A–O) A female patient aged 21 ys. with Rt. breast
lump. (A) Real-time U/S of the Rt. breast revealed benign
looking lesion, however this lesion was not fulﬁlling all criteria
of benignity, due to microlobulations. (B) Axial T1WI without
fat suppression and T2WI with fat-suppression of both breasts
(C and D) conﬁrmed the presence of an oval shaped lesion in
the right retroareolar area and two other smaller ones in the
left breast, all were hypointense in TIWI and hyperintense in
T2WI, with internal fat containing septations that are hyperin-
tense on T1WI and hypointense in T2 Fs WI. (E) T1WI with
contrast and delayed phase post contrast subtracted T1WI
(F and G) revealed homogenous intense enhancement of the
3 former lesions and an enhanced deeply seated left breast
intramammary lymph node. (H and I) TIC of a selected ROI
within the lesion showed faint type I (progressive curve withdelayed washout). However two foci showed type III curve
raising the possibility of dysplastic changes. (J) Coronal MIP
image and intensity-modulated color-coded display of the post
contrast image (K) showed no neovascularity (L) DWI (b
800 s/mm2) and corresponding ADC of the lesion (M) revealed
low signal intensity on the diffusion and high signal on the
ADC map (i.e. no restricted diffusion). The ADC value was
(1.6 · 10–3 mm2/s) suspicious areas of restricted diffusion are
seen.
(N) Minimal Choline trace was detected on spectroscopic
analysis. (O) Excision biopsy of the lesion revealed right ﬁbroade-
noma with atypical hyperplasia through histopathology.
Fig. 3 (A–Q) A female patient aged 65 ys. presented by Lt.
breast lump. (A and B) Left MLO and CC showed a mammo-
graphically an ill-deﬁned spiculated opacity in the upper outer
quadrant of the left breast with overlying clustered pleomor-
phic microcalciﬁcations. (C) Ultrasound conﬁrmed the lesions
and was ranked BI-RADS 4. This was associated with suspi-
cious globular left axillary lymph nodes with lost hilae (D)
Axial T1WI without fat suppression revealed a bizarre-
shaped hypointense breast mass lesion and relatively hyperin-
tense on axial T2WI with fat suppression (E). (F) Delayed
phase post contrast subtracted axial T1WI revealed strongly
enhanced bizarre shaped left breast focal lesion as well as left
axillary tail suspicious lymphadenopathies measuring
2.5 · 1.5 cm with eccentric or lost hilum (G) TIC of a selected
ROI within the lesion showed type III (washout curve) as well
as type II (plateau type) in other parts (H). (I, K and L) axial
3D MIP, in axial, coronal and sagittal views and color coded
mapping (J) revealed increased blood supply to the lesion
and neovascularization. (M and O) DWI (b 800 s/mm2) and
corresponding ADC map (N and P) revealed high signal inten-
sity on the diffusion and signal loss on the ADC map (i.e.
restricted diffusion). ADC value was (0.7 · 10–3 mm2/s). The
medial side of the left axillary tail lymph nodes showed an area
of restricted diffusion (ADC= 0.7 · 10–3 mm2/s) (N). (Q)
Choline trace was detected on MRS.
FNAC revealed at ﬁrst no malignancy, while excision
biopsy revealed malignant lesion. The diagnosis of invasive
lobular carcinoma was conﬁrmed pathologically.
Fig. 4 (A–Q) A female patient aged 55 ys. with history of
Rt. radical mastectomy for breast cancer and presented by
two palpable lumps at the mastectomy bed.
(A) Mammography of the Lt. breast revealed; a globular
opacity along the Lt. axillary tail (conﬁrmed at U/S. to be
lymphadenopathy with lost hilum).
(B and C) U/S. scan of the Rt. mastectomy bed revealed; a
suspected residual hypoechoic mass. The patient was ranked
BIRADS 5. (D) T1WI without fat suppression and (E)
T2WI with fat suppression in axial plane revealed; two irregu-
lar hypointense focal lesions in the mastectomy bed, with cen-
tral breakdown and inﬁltration of underlying pectoral muscle.
(F and I) T1WI with fat suppression after contrast and (G and
J) delayed phase post. contrast subtracted T1WI in axial plane
revealed; enhanced two foci associated with contralateral axil-
lary lymph node enlargement. (H) TIC of selected ROI within
one of the lesions and axillary lymph node (K) showed type III
curve (washout) in both.
(L) color coded mapping, axial views shows increased vas-
cularity of the lesion as well as contralateral lymph node (M).
(N) DWI (b800 s/mm2) in the axial plane, corresponding ADC
map of the lesion (O) and of the axillary lymph node (P). The
1-A 1-B
1-C 1-D
1-E 1-F
1-H1-G
Fig. 1 (A–M): Juvenile breast ﬁbroadenoma.
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1-I 1-J
1-K 1-L
1-M
Fig. 1 (continued)
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2-B
2-A
2-C 2-D
2-F2-E
2-G
2-H
Fig. 2 (A–O): Fibroadenoma with atypical hyperplasia.
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Fig. 2 (continued)
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Fig. 3 (A–Q): Invasive lobular carcinoma.
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Fig. 3 (continued)
MRI in diagnosis of breast masses 1225lesion showed high signal intensity of diffusion and signal loss
on the ADC map i.e. restricted diffusion. The ADC
value = 0.7 · 10–3 mm2/s. (Q) Choline traces in the contralat-
eral lymphadenopathy were detected on MRS analysis, how-
ever the lesion itself showed no choline trace. On
histopathology diagnosis of post operative recurrent mam-
mary duct carcinoma with contralateral nodal metastases
was conﬁrmed pathologically.4. Discussion
The use of MRI for screening high risk patients is now recom-
mended by almost all major medical societies. Breast cancers
in the high risk populations generally present at younger age
and screening with both mammography and MRI is recom-
mended beginning at age 30 ys. Breast MRI is clearly the most
sensitive method for breast cancer detection and speciﬁcities
are comparable if not superior to other breast imaging
methods (12).
Dynamic contrast enhanced MRI (DCE-MRI) of the
breast has a high sensitivity for the breast cancer detection
and has a recently been shown to be the most sensitive breast
screening technique for women at high risk. It is also more
accurate than mammography or ultrasound for the delineation
of the extent of the disease in patients with recent diagnosis of
cancer (2).Up to now breast MRI is analysed according to morpho-
logical criteria, enhancement kinetics and T2 characteristics
of the breast lesion. However an overlap between benign and
malignant lesions which leads to a reported speciﬁcity of about
40–80%. There is an increasing number of congress abstracts
and published studies which proves that the speciﬁcity of
breast MR could be increased using DWI and MRS studies
(13).
MRI lesions characteristics in the our study included size in
ml, type (mass, non-mass like enhancement, cystic lesion) and
BI-RADS category, this agreed with the study of Savanah and
Patridage (14). We visually analysed the enhancement charac-
teristics of the lesion from the post-contrast subtracted images
and this agreed with Kvistad (15) who made detection of
enhancing lesion easier by subtracted image.
For generation of time intensity curve (TIC) we set ROIs
based on visual inspection. TIC was obtained with the use of
a small ROI inside the mass and avoidance of central hemor-
rhagic necrosis or ﬁbrosis (16).
In our study type III curve was the most common type in
the pathologically proved malignant cases (6/10) (60%). This
correlated with Jack’s (17) study in which the type III (wash-
out) curve was detected in 32 patients out of 37 ones
(86.5%), on other hand type I a curve was seen in 5 patients
out of 10 patients with malignant lesions (50%) of our study,
compared to 10.8% in Jack, s study, Also type 1a curve was
detected in 13 benign lesions out of 21 ones (13/21) (61.9%)
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Fig. 4 (A–Q): Recurrent mammary duct carcinoma.
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study in which type 1 curve was detected in 65% of benign
breast lesions. We agreed also with Jack, s results (17) in that
there was signiﬁcant difference between malignant and benign
lesions at the distribution of curve type and in that the TIC is
useful in differentiating malignant lesions from benign ones.
The results of our study were in agree with that of Yi et al.
(18) who stated that we could acquire general information
about tumor vascular physiology, interstitial space volume
and prognostic factor by analyzing TIC without a complicated
acquisition process.
In our study we found that DCE-MRI had sensitivity
(92.3%), speciﬁcity (81%) and accuracy (85.3%).These results
were compared to that of Kul et al. (19) who reported 75.7%
sensitivity, 97.5% speciﬁcity and 88.1% accuracy. Overlap in
morphologic characteristics and kinetic features of malignant
and benign lesions caused improper classiﬁcations. In an
attempt to increase diagnostic efﬁcacy, mainly the speciﬁcity
of breast MR, we evaluated the additional role of DWI and
MRS.
We ensured that DWI was performed prior to contrast
enhancement to avoid the effect of contrast material. In some
studies however, DWI was performed after injection of con-
trast like that of the study done by S.C. Partridge et al. (20)
but actually they considered this one of the limitation of their
study and they stated that it might be preferable to acquire
DWI sequence before contrast injection.
Contrarily Janka et al. (21) study have been done to com-
pare the DWI image and ADC results before and after admin-
istration of contrast, showing that DWI after contrast
administration gives a slightly better lesion discrimination.
In our study we assessed the DWI for all cases with breast
lesions in conjunction with DCE-MRI. This was in agree withthat of Kuroki et al. (9) who stated that DWI is not a complete
method of diagnosis. In most applications the diffusion gradi-
ents are integrated in echo planar imaging (EPI) sequences
which exhibit high signal intensity in areas with restricted dif-
fusion as well as in fatty tissue. This make fat saturation tech-
niques necessary to identify the lesions in the diffusion
weighted images (13).
In our study we selected b values of 50, 400 and 800 which
were the same values chosen by Wenkel et al. (13). Liberman
et al. (22) which concluded that for good image quality and
valid differentiation between malignant and benign tumor,
the optimized b value of DWI is in the range of
600–1200 s/mm2 at 1.5 T. Our 34 studied cases were classiﬁed
according to diffusion pattern in the detected lesion into two
groups; G.I. included 25 patients without restricted diffusion
(74%) and G.II. Included 9 patients with restricted diffusion
(26%). The mean ADC value was signiﬁcantly lower
(0.5–0.9 · 103 mm2/s) for malignant lesion in comparison
with that of benign lesions (1.7–2.7 · 103 mm2/s).
Out of 10 patients with malignant lesion of our study 6
patients showed restricted diffusion and out of 21 patients with
benign breast lesions 19 patients showed non-restricted diffu-
sion. In our study we found signiﬁcant difference between
ADC values of malignant and benign breast lesions, assuming
a threshold of 1.2 · 103 mm2/s. Similarly an 2014 by Nogeria
et al. (23) study, proved DWI with complementary ADC val-
ues to be useful for the detection and characterization of breast
lesion where mean ADCs of 1.99 ± 0.27 · 103 mm2/s,
1.08 ± 0.25 · 103 mm2/s, and 1.74 ± 0.35 · 103 mm2/s,
were obtained for normal tissue, malignant, and benign lesion
respectively.
Our study reported a raised speciﬁcity from 81% to 90.5%
and a slightly improved PPV from 75% to 77.8% after
MRI in diagnosis of breast masses 1229combining DWI to DCE-MRI without any improvement in
sensitivity (53.8%). NPV was 76% and accuracy was 76.5%.
These results agreed with Kul et al. (19) who reported an
improved speciﬁcity (86.5%), sensitivity (91.5%), PPV
(89.6%), NPV (88.9%) and accuracy (89.3%). An older study
by Sonmez (24) shared nearly the same results.
The correlation between the ﬁndings of DWI and patholog-
ical results of different breast lesions showed the value of this
sequence as an additive tool that augment the results of
dynamic MRI and increase the overall speciﬁcity of the study.
This fact gains a wide agreement with a large number of studies
(25,26). DWI has some important advantages for use in com-
bined MR protocols. It is available on most commercial MR
scanners and does not need secondary gadolinium use. It has
a very short imaging time with the use of EPI. The evaluation
of the image obtained is quantitative and rather easy (24).
In our study, we have demonstrated the clinical utility of
breast 1H MRS to distinguish between malignant and benign
breast lesions by use of the composite Choline signal. All pub-
lished results suggest that there is a relationship between the
choline metabolic activity and angiogenic activity. As choline
is involved in cellular proliferation, it is logical that angiogen-
esis increases to support tumor metabolic requirements
(27,28).
In our study we found that the single-voxel proton MRS of
the breast is clinically feasible. It can be performed after stan-
dard unenhanced and contrast breast study in an examination
time of approximately 40 min, with relatively failure rate (6%),
similarly 3% failure rate reported in meta-analysis by Tse et al.
(29) of more than 280 patients. In our study, breast 1H-MR
spectroscopy was predominantly performed with qualitative
analysis of choline peak integral.
According to spectroscopic analysis of the breast lesions,
the 34 patients of our study were classiﬁed into two groups;
G.I. included 17 patients with MRS suspicious results (proba-
bly malignant where choline trace was detected) and G.II.
included 17 patients with non-suspicious MRS (probably
benign where no detectable choline trace). We found that
out of 17 patients with choline trace 9 patient showed malig-
nant lesion (9/17) (52.9%), 3 patients showed high risk lesions
(3/17)while the remained 5 patient were having benign lesions
(29.4%), while out of 17 patients without detectable choline
trace 16 patients were pathologically proven to be benign
(16/17) (94.1%). In our study we found that MRS sensitivity
was (92.3%), speciﬁcity (76.2%) and accuracy (82.4%) and
our these results were in agree with that of Rachel et al. (30)
study where sensitivity and speciﬁcity of SV-MRS were 71%
and 85% respectively.
The combination of choline presence and ADC values
achieved higher level of accuracy and speciﬁcity in discriminat-
ing malignant from benign lesions over choline presence or
ADC results alone (27). Huang et al. (31) also reported the
increase in sensitivity and speciﬁcity of the breast cancer detec-
tion when DCE-MRI, SV 1H -MRS and T2* weighted perfu-
sion MR imaging results were combined within the
examination. Speciﬁcity improved from 62.5% to 87% when
MRS ﬁnding were integrated to DCE-MRI and increased fur-
ther to 100% once perfusion MR results were considered. This
clearly highlights the beneﬁt of incorporating secondary MR
modalities into the routine breast MR examination.
Using the optimal threshold for absolute tCho, we reported
one false –ve (recurrent mammary ductal carcinoma) and 5false +ve cases (two lactating mothers, two ﬁbroadenomas
and a case of fat necrosis). The histologic type of the false –
ve lesion is not surprising because of the possibility of a rela-
tively low level of tCho in ductal carcinoma which is different
from invasive ductal cancer (29). Yeung et al. (32) reported
nine false –ve four ductal carcinoma in situ and three invasive
ductal carcinoma with an extensive in situ component.
Conversely, it is already known that some ﬁbroadenoma
may present high levels of tCho at both in vitro and in vivo
MRS (33).
Our MRS study for 34 patients with breast lesion has sev-
eral limitations. In addition to small sample size already men-
tioned, we should consider the variable ﬁlling factor caused by
the impossibility of reducing the VOI below 1 ml, thus almost
always including surrounding fat or healthy gland parench-
yma. More advanced hardware (e.g., ﬁeld strength higher than
1.5 tesla, multichannel coils) and dedicated post-processing
software could provide MR spectra of better quality than
those was obtained. Moreover approach of our study, based
on the use of arbitrary units, may not allow the application
of our cutoff value for tCho peak integral to different technical
and clinical settings. Finally the long acquisition time of our
MRS sequence (nearly 13 min) could have reduced the spectral
resolution because of the probability of artifacts from respira-
tory and other patient, s motion.
In conclusion, our experience ﬁrst showed that in vivo 1.5 T
single voxel water and fat suppressed proton MRS of the
breast can be added as a last phase after unenhanced and
DCE-MRI, with an entire examination time not longer than
40 min, Moreover we showed that breast MRS using tCho
peak integral allows high sensitivity and speciﬁcity. Studies
of large clinical series are warranted.
We agreed with 2014 multi-parametric MRI (MP MRI)
study done by Pinker et al. (34) who stated that the breast
MRI with 3 parameters (DCE-MRI, DWI, and MRS)
increased the diagnostic accuracy of breast cancer in compar-
ison with the DCE-MRI alone and MP MRI with 2 parame-
ters, yielding signiﬁcantly higher AUC (>0.90 for small
tissue sample) in comparison with DCE-MRI alone resulting
in elimination of false –ve lesions and signiﬁcantly reducing
the false +ve ones.5. Conclusion
DCE-MRI of the breast has a high sensitivity for breast cancer
detection and has been recently shown to be the most sensitive
breast screening technique for women at high risk and more
accurate than sonomammography in delineation the extent
of the disease in patients with recent diagnosis of cancer.
DWI MR detects early changes in the morphology and
physiology of the tissue. It has a potential role for characteri-
zation of the breast masses and treatment monitoring after
chemotherapy.
Combining DWI to DCE-MRI improves the discrimina-
tion power of malignant from benign breast lesion and
increases the overall accuracy of MRI and reduces the unnec-
essary invasive procedures.
MRS of the breast provides molecular information in non-
invasive manner.
The combination of choline presence and ADC values
achieved higher level of accuracy and speciﬁcity in
1230 A.H. Teama et al.discriminating malignant from benign lesion over choline pres-
ence or ADC alone.
The speciﬁcity improved also when MRS ﬁndings were inte-
grated to DCE-MRI. This clearly highlights the beneﬁt of
incorporating secondary modalities into routine breast MR
examination for elimination of the false –ve lesions and reduc-
ing the false +ve lesions.
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